智通财经APP获悉，和铂医药-B(02142)再涨近6%，12月16日至今股价累计涨幅接近200%。截至发稿，涨5.66%，报3.36港元，成交额1314.32万港元。
消息面上，和铂医药公告，1月23日，公司耗资321.9万港元回购102万股。据悉，今年1月2日，和铂医药发布公告，根据购回授权，其拟不时于公开市场上购回价值不超过4000万港元的股份。董事会认为，公司股票的当前市场交易价格远远低估了公司的内在价值及业务前景。
此外，和铂医药近期宣布，与科伦博泰就HBM9378/SKB378与Windward Bio签订许可协议。Windward Bio获得HBM9378/SKB378在全球范围内（不包括大中华区以及部分东南亚及西亚国家）进行研究、开发、生产和商业化的独家授权。授权方有权收取最多合共9.7亿美元预付款及里程碑付款以及占净销售额个位数到双位数百分比的分层特许权使用费。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.